Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cangene Announces Extension of VIGIV Biodefence Contract with U.S. Government

Published: Friday, September 27, 2013
Last Updated: Friday, September 27, 2013
Bookmark and Share
Contract with CDC for the supply of VIGIV extended by 18 months.

Cangene Corporation (Cangene) has announced that the scope of work under its contract with the Centers for Disease Control and Prevention (CDC) for the supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile has been expanded.

The contract, which relates to United States Government biodefence programs, has been extended by 18 months and has also been modified to include three additional option periods that extend through 2017.

Under the terms of the contract extension, Cangene will conduct additional services to support licensure maintenance activities for VIGIV that could generate up to approximately $6.9 million in revenue for Cangene over the next 18 months.

In addition, the contract extension includes future optional services to support licensure maintenance activities for the product, as well as options for additional manufacturing and plasma collections.

The optional periods, if exercised, could generate an additional $45 million in revenue if the baseline scope of work is implemented or up to an additional $77 million in revenue if the maximum scope is implemented.

John A. Sedor, President and CEO of Cangene, said: "The extension of our VIGIV contract underscores Cangene's leadership in biodefence contracting, which complements our pipeline-focused strategy in the specialty biopharmaceutical space. We look forward to continuing to work together with the U.S. Government and the CDC to ensure preparedness against the threat of smallpox."

VIGIV is a hyperimmune product to be used in treating and preventing certain types of severe complications that may be associated with smallpox vaccination, and is considered an important component of smallpox vaccination programs.

The Company originally entered into a 5-year contract for the supply of VIGIV in 2002, which was extended to a 10-year term, before entering into a new contract with the Centers for Disease Control and Prevention in 2012.

Cangene's VIGIV product was first accepted into the U.S. Strategic National Stockpile in 2002 and was subsequently licensed in the United States by the U.S. Food and Drug Administration in 2005 and in Canada by Health Canada in 2007.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cangene to be Acquired by Emergent BioSolutions for US$222 Million
Cangene shareholders to receive US$3.24 per share (C$3.44 per share) in cash.
Friday, December 13, 2013
FDA Lifts Clinical Hold on Cangene's Hemophilia Compound IB1001
Cangene will begin new studies in adult and pediatric patients.
Tuesday, July 30, 2013
Cangene Announces Agreement to Acquire Late Stage Hemophilia B Product
Cangene will pay approximately $5.9 million upfront for IB1001.
Thursday, February 07, 2013
Cangene Reports First Quarter 2013 Results
Earnings of 7 Cents per share.
Monday, December 17, 2012
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!